VOR
VOR 1-star rating from Upturn Advisory

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR) 1-star rating from Upturn Advisory
$8.18
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: VOR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

2 star rating from financial analysts

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $50.33

1 Year Target Price $50.33

Analysts Price Target For last 52 week
$50.33 Target price
52w Low $2.62
Current$8.18
52w High $65.8

Analysis of Past Performance

Type Stock
Historic Profit -60.68%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 179.23M USD
Price to earnings Ratio -
1Y Target Price 50.33
Price to earnings Ratio -
1Y Target Price 50.33
Volume (30-day avg) 5
Beta 2.08
52 Weeks Range 2.62 - 65.80
Updated Date 12/6/2025
52 Weeks Range 2.62 - 65.80
Updated Date 12/6/2025
Dividends yield (FY) -
Basic EPS (TTM) -386.86

Earnings Date

Report Date 2025-11-07
When -
Estimate -0.104
Actual -121.63

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -144.27%
Return on Equity (TTM) -125.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 19056461
Price to Sales(TTM) -
Enterprise Value 19056461
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.09
Shares Outstanding 21910630
Shares Floating 8911499
Shares Outstanding 21910630
Shares Floating 8911499
Percent Insiders 8.98
Percent Institutions 26.84

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Vor Biopharma Inc

Vor Biopharma Inc(VOR) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Vor Biopharma, Inc. is a clinical-stage cell and gene therapy company founded in 2016 and based in Cambridge, Massachusetts. It focuses on developing engineered hematopoietic stem cell (eHSC) therapies to treat hematological malignancies, aiming to improve outcomes for patients undergoing hematopoietic stem cell transplantation (HSCT).

Company business area logo Core Business Areas

  • Engineered Hematopoietic Stem Cell (eHSC) Therapies: Vor Biopharma is focused on developing eHSC therapies to protect patients undergoing HSCT from relapse. Their lead product candidate is VOR33, an eHSC product designed to eliminate target cancer cells from the patient's body.

leadership logo Leadership and Structure

Robert Ang, MD, PhD is the President and CEO. The leadership team consists of various executives in research, development, and operations. The company operates with a structure common for clinical-stage biotech firms, focused on R&D and clinical trials.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • VOR33: VOR33 is Vor Biopharma's lead product candidate, an eHSC therapy in clinical development for acute myeloid leukemia (AML). It is designed to enable targeted cancer therapies. As a pre-commercial product, there is no market share data. Competitors include companies developing other AML therapies, like Bristol Myers Squibb (Onureg) and AbbVie/Roche (Venclexta).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and dynamic, with a focus on developing innovative therapies for unmet medical needs. Vor Biopharma operates within the cell and gene therapy segment, specifically targeting hematological malignancies.

Positioning

Vor Biopharma is positioned as an innovator in the eHSC therapy space. Their competitive advantage lies in their unique approach to engineering hematopoietic stem cells to improve HSCT outcomes and enable targeted therapies.

Total Addressable Market (TAM)

The global market for acute myeloid leukemia (AML) treatment is significant, projected to reach billions of dollars. Vor Biopharma's positioning is focused on capturing a portion of this market by improving HSCT outcomes and enabling targeted therapies. The actual value of TAM depends on clinical success and regulatory approval of VOR33

Upturn SWOT Analysis

Strengths

  • Novel eHSC technology platform
  • Focus on unmet need in hematological malignancies
  • Experienced leadership team

Weaknesses

  • Clinical-stage company with no approved products
  • Reliance on successful clinical trial outcomes
  • High cash burn rate

Opportunities

  • Potential for breakthrough therapy designation
  • Partnerships with larger pharmaceutical companies
  • Expansion to other hematological malignancies

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established therapies
  • Difficulty in raising capital

Competitors and Market Share

Key competitor logo Key Competitors

  • BMY
  • ABBV
  • ARRY

Competitive Landscape

Vor Biopharma's advantage is its novel eHSC platform. Disadvantages include the risks associated with clinical-stage companies and competition from established therapies.

Growth Trajectory and Initiatives

Historical Growth: Vor Biopharma's growth is characterized by advancing its eHSC platform and progressing VOR33 through clinical trials.

Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approval of VOR33. Analyst estimates vary depending on the perceived likelihood of success. The growth trajectory depends entirely on VOR33 progressing through trials and regulatory approval.

Recent Initiatives: Recent initiatives include advancing the Phase 1/2 clinical trial of VOR33, presenting data at scientific conferences, and securing additional funding.

Summary

Vor Biopharma is a clinical-stage company pioneering eHSC therapies, with a focus on improving HSCT outcomes in hematological malignancies. The company's success hinges on the progression of VOR33 through clinical trials. They face risks common to biotech firms, including clinical trial setbacks and funding challenges. A successful clinical trial and a commercialization strategy are key. They should be aware of the competitors in the space.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Yahoo Finance

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vor Biopharma Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2021-02-05
Chairman & CEO Dr. Jean-Paul Kress M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 154
Full time employees 154

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.